Medicosnext
After government approval of Sputnik V, Russia’s first COVID-19 vaccine, on August 11, 2020, health authorities have, on October 14, 2020, approved its second vaccine, EpiVacCorona, developed by Novosibirsk’s Vektor [State Virology and Biotechnology Center], as it starts large-scale trials. According to President Putin, his deputy prime minister and the head of the country’s consumer safety watchdog have both received the vaccine as part of the trials, which earlier had been found to be successful in 100 volunteers. Vektor, which plans to produce the first 60,000 doses of EpiVacCorona soon, will conduct post-registration trials on 40,000 volunteers across the country. A third coronavirus vaccine is expected to receive approval in December.
Ref: Th e Moscow Times, October 14, 2020,
